Sign in

    Ted Tenthoff

    Managing Director and Senior Research Analyst at Piper Sandler & Co.

    Ted Tenthoff is a Managing Director and Senior Research Analyst at Piper Sandler, specializing in the biotech industry with a particular focus on drug discovery and gene editing. He covers numerous companies including CRISPR Therapeutics, Intellia Therapeutics, Moderna, and Vertex Pharmaceuticals, and has authored influential sector research such as Piper Sandler’s BioInsights reports; his analyst performance includes a 41% success rate and an average return near breakeven from over 170 ratings, though his most profitable call yielded a 366% gain. Tenthoff joined Piper Sandler in 2003 after prior roles covering genomics at Robertson Stephens & Company and as a medical technology analyst at Lehman Brothers, and he previously earned top stock-picker rankings from The Wall Street Journal and Starmine Analyst Awards. He holds a bachelor’s degree from the University of Pennsylvania and is professionally registered with FINRA, demonstrating his credentials in equity research for healthcare and biotechnology.

    Ted Tenthoff's questions to Karyopharm Therapeutics (KPTI) leadership

    Ted Tenthoff's questions to Karyopharm Therapeutics (KPTI) leadership • Q2 2025

    Question

    Ted Tenthoff of Piper Sandler Companies inquired about Karyopharm's biggest concerns for the upcoming myelofibrosis (MF) data readout and how the company is preparing for three major data readouts in 2026 across myelofibrosis, endometrial cancer, and multiple myeloma.

    Answer

    CEO Richard Paulson stated the company is excited for the opportunity and well-prepared, highlighting the significant prescriber overlap between multiple myeloma, myelofibrosis, and endometrial cancer which allows for leveraging existing commercial capabilities. Chief Medical Officer Reshma Rangwala added that she is not worried but rather encouraged by the comprehensive data for selinexor in MF, which has shown compelling improvements in SVR35, TSS, and disease modification markers, suggesting the potential to meaningfully improve upon the standard of care.

    Ask Fintool Equity Research AI

    Ted Tenthoff's questions to ARVINAS (ARVN) leadership

    Ted Tenthoff's questions to ARVINAS (ARVN) leadership • Q2 2025

    Question

    Ted Tenthoff inquired about the allocation of restructuring costs between R&D and G&A, and asked for more detail on the expected ARV-102 data release later in the year, specifically for the single ascending dose cohorts in Parkinson's patients.

    Answer

    CFO Andrew Saik clarified that restructuring costs were split between R&D and G&A, with most stock-based compensation in R&D. CMO Noah Berkowitz added that for ARV-102, the company expects to present the full healthy volunteer dataset and initial single ascending dose (SAD) data from Parkinson's patients at an upcoming conference, which should signal the program is on track compared to healthy volunteer results.

    Ask Fintool Equity Research AI

    Ted Tenthoff's questions to Cellectar Biosciences (CLRB) leadership

    Ted Tenthoff's questions to Cellectar Biosciences (CLRB) leadership • Q2 2024

    Question

    Ted Tenthoff of Piper Sandler & Co. asked for an update on the remaining work for the NDA submission and whether the company anticipates an FDA Advisory Committee (ODAC) meeting for iopofosine.

    Answer

    COO Jarrod Longcor explained that most NDA modules are complete, with the primary remaining task being the integration of the final CLOVER-WaM clinical study report. Regarding a potential ODAC meeting, Longcor said he wouldn't be surprised by a request, while SVP, Medical, Dr. Andrei Shustov, called it a 'tossup' but confirmed the company is preparing for the possibility.

    Ask Fintool Equity Research AI

    Ted Tenthoff's questions to Cue Biopharma (CUE) leadership

    Ted Tenthoff's questions to Cue Biopharma (CUE) leadership • Q3 2023

    Question

    Inquired about the expansion of the Immuno-STAT platform beyond the current clinical assets, specifically asking about other antigens like KRAS and whether potential partners are interested in existing products or using their own proprietary antigens with the platform.

    Answer

    The company is expanding its pipeline to target primary cancer drivers like mutated KRAS (G12V, G12D), MAGE-A4, and PRAME. There is interest from potential partners in both the company's existing pipeline and in deploying the platform for their own bespoke antigens. The Neo-STAT platform is highlighted as a flexible solution for this, enabling a 'plug-and-play' approach for various antigens and personalized immunotherapy.

    Ask Fintool Equity Research AI

    Ted Tenthoff's questions to Marker Therapeutics (MRKR) leadership

    Ted Tenthoff's questions to Marker Therapeutics (MRKR) leadership • Q3 2019

    Question

    Ted Tenthoff of Piper Jaffray sought clarification on the specific issues causing the IND hold for the AML trial and the expected timeline for resolution.

    Answer

    SVP of Clinical Development, Dr. Mythili Koneru, explained the hold relates to FDA requests for quality and technical data on two third-party reagents used in manufacturing, which are not present in the final product. She confirmed a complete response was submitted on October 28, 2019, with a 30-day FDA review period. President and CEO Peter Hoang added that such requests are not atypical in the cell therapy space.

    Ask Fintool Equity Research AI